医薬品ロジスティクスの日本市場：タイプ別、作業別、コンポーネント別、アプリケーション別、オペレーション別、地域別、機会、予測、2019年～2033年

日本の医薬品ロジスティクス市場は、医薬品需要の伸び、医薬品サプライチェーンの複雑化、厳格な規制要件により、2026～2033年の予測期間中にCAGR 5.93%を記録し、2025年の532万米ドルから2033年には843万米ドルまで成長すると予測されます。日本の医薬品ロジスティクス市場は、精度、規制、イノベーションの交差点に位置しています。日本では、バイオ医薬品、特殊医薬品、個別化医療を含む高価値の治療薬に対する需要の高まりに直面しており、安全でコンプライアンスを遵守し、タイムリーなデリバリーを確保するというプレッシャーがこれまで以上に重要になっています。高齢化が進み、規制要件が厳しい日本では、ロジスティクスパートナーは単に配送するだけでなく、最後の1キロに至るまで治療の完全性を維持することが求められています。

COVID以降、日本はコールドチェーンインフラ、自動化、リアルタイムモニタリング技術への投資を加速させ、ロジスティクスをバックエンドのコストセンターから、医療アクセスを可能にするフロントラインへと変貌させました。摂氏2度の変動で貨物が無価値になりかねないこの業界では、温度の逸脱、輸送の遅延、手作業によるミスは今や容認できないです。

例えば、武田薬品工業は2023年9月、三菱倉庫・JR貨物と提携し、医薬品の温度管理鉄道輸送ソリューションを試験的に導入しました。この取り組みは、GDPに準拠した厳格な温度管理を維持し、振動リスクを軽減しながら、CO2排出量を60％削減するという、従来の陸上輸送方法からの大幅な転換を実現したもので、この種の鉄道を利用した医薬品ロジスティクスシステムとしては日本初のものです。

目次

第1章 プロジェクトの範囲と定義

第2章 調査手法

第3章 米国の関税の影響

第4章 エグゼクティブサマリー

第5章 顧客の声

• 企業経験と専門知識
• インフラとテクノロジー
• 世界なリーチとネットワーク
• リスク管理と保険

第6章 日本の医薬品ロジスティクス市場の展望、2019年～2033年

• 市場規模分析と予測
  • 金額別
• 市場シェア分析と予測
  • タイプ別
    • コールドチェーンロジスティクス
    • 非コールドチェーンロジスティクス
  • 作業別
    • ピッキング
    • 保管
    • 検索システム
    • ハンドリングシステム
  • コンポーネント別
    • 保管
    • 輸送
    • 監視コンポーネント
  • アプリケーション別
    • 化学品・医薬品
    • バイオ医薬品
    • 特殊医薬品
  • オペレーション別
    • 海路
    • 道路
    • 鉄道
    • 航空
    • 保管・サービス
  • 地域別
    • 北
    • 中央
    • 南
  • 企業別市場シェア分析（上位5社・その他- 金額ベース、2025年）
• 2025年市場マップ分析
  • タイプ別
  • 作業別
  • コンポーネント別
  • アプリケーション別
  • オペレーション別
  • 地域別

第7章 需要供給分析

第8章 バリューチェーン分析

第9章 ポーターのファイブフォース分析

第10章 PESTLE分析

第11章 市場力学

• 市場促進要因
• 市場の課題

第12章 市場動向と発展

第13章 政策と規制状況

第14章 ケーススタディ

第15章 競合情勢

• 市場リーダー上位5社の競合マトリックス
• トップ5社のSWOT分析
• 市場トップ10社の主要企業の情勢
  • AP MOLLER-MAERSK A/S
  • CEVA Logistics SA
  • Nippon Express Co., Ltd.
  • Logisteed Ltd.
  • Kintetsu World Express, Inc.
  • Yamato Transport Co., Ltd.
  • Sagawa Express Co., Ltd.
  • Yusen Logistics Co., Ltd.
  • Mitsubishi Logistics Corporation
  • DHL International GmbH

第16章 戦略的提言

第17章 調査会社について・免責事項

List of Tables

• Table 1. Competition Matrix of Top 5 Market Leaders
• Table 2. Mergers & Acquisitions/ Joint Ventures (If Applicable)
• Table 3. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

• Figure 1. Japan Pharmaceutical Logistics Market, By Value, In USD Million, FY2019-FY2033F
• Figure 2. Japan Pharmaceutical Logistics Market Share (%), By Type, FY2019-FY2033F
• Figure 3. Japan Pharmaceutical Logistics Market Share (%), By Procedure, FY2019-FY2033F
• Figure 4. Japan Pharmaceutical Logistics Market Share (%), By Component, FY2019-FY2033F
• Figure 5. Japan Pharmaceutical Logistics Market Share (%), By Application, FY2019-FY2033F
• Figure 6. Japan Pharmaceutical Logistics Market Share (%), By Operation, FY2019-FY2033F
• Figure 7. Japan Pharmaceutical Logistics Market Share (%), By Region, FY2019-FY2033F
• Figure 8. By Type Map-Market Size (USD Million) & Growth Rate (%), FY2025
• Figure 9. By Procedure Map-Market Size (USD Million) & Growth Rate (%), FY2025
• Figure 10. By Component Map-Market Size (USD Million) & Growth Rate (%), FY2025
• Figure 11. By Application Map-Market Size (USD Million) & Growth Rate (%), FY2025
• Figure 12. By Operation Map-Market Size (USD Million) & Growth Rate (%), FY2025
• Figure 13. By Region Map-Market Size (USD Million) & Growth Rate (%), FY2025

Japan pharmaceutical logistics market is projected to witness a CAGR of 5.93% during the forecast period FY2026-FY2033, growing from USD 5.32 million in FY2025 to USD 8.43 million in FY2033 due to growth in pharmaceutical demand, increasing complexity of pharmaceutical supply chains, and stringent regulatory requirements. Japan pharmaceutical logistics market stands at the intersection of precision, regulation, and innovation. As the country faces a rising demand for high-value therapeutics, including biopharma, specialty drugs, and personalized medicine, the pressure to ensure safe, compliant, and timely delivery is more critical than ever. With Japan's aging population and strict regulatory requirements, logistics partners are not just expected to deliver, they are also expected to preserve therapeutic integrity down to the last kilometer.

Post-COVID, the country has accelerated investments in cold chain infrastructure, automation, and real-time monitoring technologies, transforming logistics from a back-end cost center into a front-line enabler of healthcare access. Temperature excursions, transit delays, and manual errors are now unacceptable in an industry where 2 degrees Celsius fluctuation can render a shipment worthless.

For instance, in September 2023, Takeda Pharmaceutical partnered with Mitsubishi Logistics and JR Freight to pilot a temperature-controlled rail transport solution for pharmaceuticals. This initiative marked a significant shift from conventional road methods, achieving a 60% reduction in CO2 emissions while maintaining strict GDP-compliant temperature control and mitigating vibration risks, representing the first rail-based pharmaceutical logistics system of its kind in Japan.

Surge in Cold Chain Logistics for Biopharma and Vaccines Fuels Market Growth

Japan's biopharmaceutical sector has expanded rapidly, from monoclonal antibodies to mRNA-based treatments, and these drugs require stable cold chain environments to maintain efficacy. This has triggered a nationwide upgrade in temperature-controlled logistics.

In November 2023, Bushu Pharmaceuticals Ltd. opened the Soka Packaging Center, its 5th base in Japan, inside Prologis Park Soka. This state-of-the-art facility, featuring advanced ecological and safety technologies, offers extensive storage and packaging services for biological and regenerative medical products. The center's capabilities include storing 1,671 pallets at 2-8 degrees Celsius and providing easy access to refrigerated storage from truck berths. This expansion helps Bushu Pharma meet the growing demand for pharmaceutical medicines by ensuring optimal cold storage supply chain operations, contributing to Japan's cold chain logistics market's growth through enhanced efficiency, technology adoption, and ecological sustainability.

In March 2024, Yusen Logistics Co., Ltd. received CEIV Pharma recertification for its Narita International Airport facility as of March 13, 2024. The Narita Healthcare Terminal, opened in 2023, is now certified for pharmaceutical handling and operates in full compliance with Good Distribution Practice (GDP). The facility features advanced temperature controls, supporting pharmaceutical cargo at -20 degrees Celsius, +5 degrees Celsius, and +20 degrees Celsius, to accommodate a wide range of temperature-sensitive medicines.

Hospital-Focused Distribution and Urban Last-Mile Innovation to Shape the Market

Urban healthcare facilities in Japan, especially in Tokyo and Osaka, require strict delivery SLAs for specialty drugs, blood products, and urgent-care items. To meet these demands, logistics companies are innovating last-mile solutions suited for dense urban geographies. Urban-centric innovation in healthcare logistics is becoming a key differentiator in provider partnerships and SLA bidding.

For example, in June 2024, CONCOR (Container Corporation of India Ltd.) and Innovation Thru Energy (ITE), Japan, teamed up to introduce ice battery technology in containers for temperature-sensitive cargo, eliminating the need for diesel generators and maintaining freshness for up to 72 hours. This environmentally friendly solution reduces CO2 emissions by 70-80% and enhances the efficiency of cold chain logistics.

Dominance of Specialized Pharma in Logistics Demand

In Japan, specialized pharmaceuticals, including oncology drugs, orphan disease treatments, biosimilars, and advanced therapy medicinal products (ATMPs) such as cell and gene therapies, are rapidly becoming the most logistics-intensive and commercially valuable segment of pharmaceutical logistics. As Japan's aging population drives a rise in complex, chronic, and rare conditions, the healthcare system is moving toward precision therapies that require strict temperature controls, tighter delivery windows, and near-zero error tolerance. These products often carry short shelf lives, high unit value, and sensitivity to vibration or light, making them especially dependent on specialized logistics networks.

In August 2023, Mitsubishi Logistics Corporation responded to this trend by enhancing its biopharma transport suite with a cloud-integrated logistics visibility platform. The system enables pharmaceutical clients to monitor real-time shipment conditions across storage hubs, roadways, and hospital endpoints, with support for 2 degrees Celsius -8 degrees Celsius, -20 degrees Celsius, and ultra-cold chain below -70 degrees Celsius specifications.

Meanwhile, in February 2025, Essential Pharma Limited ("Essential Pharma") and Clinigen Group plc ("Clinigen") announced an expansion of their JAPAC collaboration to enhance patient access to four therapies in Japan and Korea and strengthen their joint market presence in the region. The expanded partnership includes new market authorisation transfers and exclusive distribution agreements. Building on their 2024 agreement for IOPIDINE (apraclonidine) in Korea, the companies have now extended this arrangement to Japan.

Impact of U.S. Tariffs on Japan Pharmaceutical Logistics Market

U.S. tariffs on pharmaceutical ingredients and packaging supplies-especially those sourced from China and rerouted via U.S. suppliers-have caused upstream pricing volatility. Japanese pharmaceutical manufacturers have had to adapt by sourcing APIs and sterile packaging from alternate regions (e.g., India, Europe), adding pressure on logistics timelines and import scheduling.

To avoid tariff-induced bottlenecks, Japanese logistics firms have re-routed critical pharma shipments away from U.S. transshipment hubs, especially for high-value biopharmaceuticals. This shift has led to increased reliance on regional air cargo routes (via Incheon, Singapore, or Dubai), changing the way 3PLs and 4PLs structure cold chain handoffs and storage.

Higher import costs and trade friction have incentivized Japanese pharma companies to localize more of their logistics infrastructure - investing in domestic GDP-certified cold storage, regional fulfillment hubs, and automated handling systems. This is especially true for firms distributing to hospitals, where lead time and compliance are critical.

Key Players Landscape and Outlook

Japan pharmaceutical logistics market is led by a mix of domestic giants and global specialists. Companies offer end-to-end cold chain, GDP-certified storage, and hospital delivery across all prefectures. Whereas, Yusen Logistics and Sagawa Express are rapidly digitizing operations with IoT and temperature-mapping solutions tailored to Japanese geography. International players provide value in air-sea integration and biosecure customs clearance. Logisteed and Kintetsu World Express are developing niche services in research sample handling and biopharma packaging. As regulatory pressures increase, service providers are competing on audit-readiness, SLA precision, and pharma-centric innovation, not just speed or cost.

For instance, in February 2025, Logisteed, Ltd. opened its new Kansai Logistics Center (Kyoto Kameoka) in Kameoka City, Kyoto Prefecture. Operated by Logisteed Chemical, Ltd., the state-of-the-art facility features seven warehouses and specializes in the handling of hazardous materials. Strategically located in a major industrial area with excellent transport links, the center ensures regulatory compliance for the storage of hazardous goods across sectors, including chemicals, cosmetics, pharmaceuticals, and lithium batteries, further strengthening customer supply chains in the pharmaceutical industry.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Impact of U.S. Tariffs

4. Executive Summary

5. Voice of Customers

• 5.1. Company Experience and Expertise
• 5.2. Infrastructure and Technology
• 5.3. Global Reach and Network
• 5.4. Risk Management and Insurance

6. Japan Pharmaceutical Logistics Market Outlook, FY2019-FY2033F

• 6.1. Market Size Analysis & Forecast
  • 6.1.1. By Value
• 6.2. Market Share Analysis & Forecast
  • 6.2.1. By Type
    • 6.2.1.1. Cold Chain Logistics
    • 6.2.1.2. Non-Cold Chain Logistics
  • 6.2.2. By Procedure
    • 6.2.2.1. Picking
    • 6.2.2.2. Storage
    • 6.2.2.3. Retrieval Systems
    • 6.2.2.4. Handling Systems
  • 6.2.3. By Component
    • 6.2.3.1. Storage
    • 6.2.3.2. Transportation
    • 6.2.3.3. Monitoring Component
  • 6.2.4. By Application
    • 6.2.4.1. Chemical Pharma
    • 6.2.4.2. Biopharma
    • 6.2.4.3. Specialized Pharma
  • 6.2.5. By Operation
    • 6.2.5.1. Seaways
    • 6.2.5.2. Roadways
    • 6.2.5.3. Railways
    • 6.2.5.4. Airways
    • 6.2.5.5. Storage and Services
  • 6.2.6. By Region
    • 6.2.6.1. North
    • 6.2.6.2. Central
    • 6.2.6.3. South
  • 6.2.7. By Company Market Share Analysis (Top 5 Companies and Others - By Value, FY2025)
• 6.3. Market Map Analysis, FY2025
  • 6.3.1. By Type
  • 6.3.2. By Procedure
  • 6.3.3. By Component
  • 6.3.4. By Application
  • 6.3.5. By Operation
  • 6.3.6. By Region

7. Demand Supply Analysis

8. Value Chain Analysis

9. Porter's Five Forces Analysis

10. PESTLE Analysis

11. Market Dynamics

• 11.1. Market Drivers
• 11.2. Market Challenges

12. Market Trends and Developments

13. Policy and Regulatory Landscape

14. Case Studies

15. Competitive Landscape

• 15.1. Competition Matrix of Top 5 Market Leaders
• 15.2. SWOT Analysis for Top 5 Players
• 15.3. Key Players Landscape for Top 10 Market Players
  • 15.3.1. A.P. MOLLER - MAERSK A/S
    • 15.3.1.1. Company Details
    • 15.3.1.2. Key Management Personnel
    • 15.3.1.3. Products and Services
    • 15.3.1.4. Financials (As Reported)
    • 15.3.1.5. Key Market Focus and Geographical Presence
    • 15.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisition
  • 15.3.2. CEVA Logistics SA
  • 15.3.3. Nippon Express Co., Ltd.
  • 15.3.4. Logisteed Ltd.
  • 15.3.5. Kintetsu World Express, Inc.
  • 15.3.6. Yamato Transport Co., Ltd.
  • 15.3.7. Sagawa Express Co., Ltd.
  • 15.3.8. Yusen Logistics Co., Ltd.
  • 15.3.9. Mitsubishi Logistics Corporation
  • 15.3.10. DHL International GmbH

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

16. Strategic Recommendations

17. About Us and Disclaimer